Nuwiq, Vihuma (simoctocog alfa) is a protein pharmaceutical. Simoctocog alfa was first approved as Nuwiq on 2014-07-22. It is used to treat factor VII deficiency, hemophilia a, hemorrhage, and von willebrand diseases in the USA. It has been approved in Europe to treat hemophilia a.
|Trade Name||Nuwiq, Vihuma|
|Common Name||Simoctocog alfa|
|Indication||factor vii deficiency, hemophilia a, hemorrhage, von willebrand diseases|